FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946435265> ?p ?o ?g. }

• W2946435265 endingPage "4778" @default.
• W2946435265 startingPage "4770" @default.
• W2946435265 abstract "Abstract Thyroid carcinoma is the most common endocrine malignancy. Surgery, post‐operative selective iodine‐131 and thyroid hormone suppression were the most common methods for the therapy of thyroid carcinoma. Although most patients with differentiated thyroid carcinoma ( DTC ) showed positive response for these therapeutic methods, some patients still have to face the radioactive iodine ( RAI )‐refractory problems. Sorafenib is an oral multikinase inhibitor for patients with advanced RAI refractory DTC . However, the side effects and drug resistance of sorafenib suggest us to develop novel drugs and strategies for the therapy of thyroid carcinoma. In this study, we firstly found that patients with sorafenib resistance showed no significant change in rapidly accelerated fibrosarcoma and VEGFR expression levels compared with sorafenib sensitive patients. Moreover, a further mi RNA s screen by qRT ‐ PCR indicated that miR‐124‐3p and miR‐506‐3p (miR‐124/506) were remarkably reduced in sorafenib insensitive patients. With a bioinformatics prediction and functional assay validation, we revealed that enhancer of zeste homolog 2 ( EZH 2) was the direct target for miR‐124/506. Interestingly, we finally proved that the sorafenib resistant cells regained sensitivity for sorafenib by EZH 2 intervention with miR‐124/506 overexpression or EZH 2 inhibitor treatment in vitro and in vivo, which will lead to the decreased tri‐methylation at lysine 27 of histone H3 (H3K27me3) and increased acetylated lysine 27 of histone H3 (H3K27ac) levels. Therefore, we conclude that the suppression of EZH 2 represents a potential target for thyroid carcinoma therapy." @default.
• W2946435265 created "2019-05-29" @default.
• W2946435265 creator A5020410951 @default.
• W2946435265 creator A5023874610 @default.
• W2946435265 creator A5038210379 @default.
• W2946435265 creator A5051458503 @default.
• W2946435265 creator A5061128530 @default.
• W2946435265 date "2019-05-13" @default.
• W2946435265 modified "2023-09-24" @default.
• W2946435265 title "Targeting <scp>EZH</scp> 2 as a novel therapeutic strategy for sorafenib‐resistant thyroid carcinoma" @default.
• W2946435265 cites W1990378797 @default.
• W2946435265 cites W2015132841 @default.
• W2946435265 cites W2034988175 @default.
• W2946435265 cites W2040268038 @default.
• W2946435265 cites W2068206525 @default.
• W2946435265 cites W2096474115 @default.
• W2946435265 cites W2100543217 @default.
• W2946435265 cites W2115068822 @default.
• W2946435265 cites W2135440815 @default.
• W2946435265 cites W2153734475 @default.
• W2946435265 cites W2158801409 @default.
• W2946435265 cites W2161257336 @default.
• W2946435265 cites W2162296692 @default.
• W2946435265 cites W2175101940 @default.
• W2946435265 cites W2177175549 @default.
• W2946435265 cites W2272984102 @default.
• W2946435265 cites W2312782750 @default.
• W2946435265 cites W2513912419 @default.
• W2946435265 cites W2525949435 @default.
• W2946435265 cites W2603577764 @default.
• W2946435265 cites W2605149091 @default.
• W2946435265 cites W2748506206 @default.
• W2946435265 cites W2769856168 @default.
• W2946435265 cites W2772152366 @default.
• W2946435265 cites W2783734115 @default.
• W2946435265 cites W2793681822 @default.
• W2946435265 cites W2808831695 @default.
• W2946435265 cites W2896392811 @default.
• W2946435265 cites W2897544641 @default.
• W2946435265 cites W2899300474 @default.
• W2946435265 doi "https://doi.org/10.1111/jcmm.14365" @default.
• W2946435265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6584518" @default.
• W2946435265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31087496" @default.
• W2946435265 hasPublicationYear "2019" @default.
• W2946435265 type Work @default.
• W2946435265 sameAs 2946435265 @default.
• W2946435265 citedByCount "18" @default.
• W2946435265 countsByYear W29464352652020 @default.
• W2946435265 countsByYear W29464352652021 @default.
• W2946435265 countsByYear W29464352652022 @default.
• W2946435265 countsByYear W29464352652023 @default.
• W2946435265 crossrefType "journal-article" @default.
• W2946435265 hasAuthorship W2946435265A5020410951 @default.
• W2946435265 hasAuthorship W2946435265A5023874610 @default.
• W2946435265 hasAuthorship W2946435265A5038210379 @default.
• W2946435265 hasAuthorship W2946435265A5051458503 @default.
• W2946435265 hasAuthorship W2946435265A5061128530 @default.
• W2946435265 hasBestOaLocation W29464352651 @default.
• W2946435265 hasConcept C104317684 @default.
• W2946435265 hasConcept C121608353 @default.
• W2946435265 hasConcept C126322002 @default.
• W2946435265 hasConcept C134018914 @default.
• W2946435265 hasConcept C143998085 @default.
• W2946435265 hasConcept C185592680 @default.
• W2946435265 hasConcept C2777546739 @default.
• W2946435265 hasConcept C2778019345 @default.
• W2946435265 hasConcept C2778695046 @default.
• W2946435265 hasConcept C2779399171 @default.
• W2946435265 hasConcept C2779490328 @default.
• W2946435265 hasConcept C2779761222 @default.
• W2946435265 hasConcept C2993294228 @default.
• W2946435265 hasConcept C33288867 @default.
• W2946435265 hasConcept C50171091 @default.
• W2946435265 hasConcept C502942594 @default.
• W2946435265 hasConcept C526584372 @default.
• W2946435265 hasConcept C55493867 @default.
• W2946435265 hasConcept C71924100 @default.
• W2946435265 hasConceptScore W2946435265C104317684 @default.
• W2946435265 hasConceptScore W2946435265C121608353 @default.
• W2946435265 hasConceptScore W2946435265C126322002 @default.
• W2946435265 hasConceptScore W2946435265C134018914 @default.
• W2946435265 hasConceptScore W2946435265C143998085 @default.
• W2946435265 hasConceptScore W2946435265C185592680 @default.
• W2946435265 hasConceptScore W2946435265C2777546739 @default.
• W2946435265 hasConceptScore W2946435265C2778019345 @default.
• W2946435265 hasConceptScore W2946435265C2778695046 @default.
• W2946435265 hasConceptScore W2946435265C2779399171 @default.
• W2946435265 hasConceptScore W2946435265C2779490328 @default.
• W2946435265 hasConceptScore W2946435265C2779761222 @default.
• W2946435265 hasConceptScore W2946435265C2993294228 @default.
• W2946435265 hasConceptScore W2946435265C33288867 @default.
• W2946435265 hasConceptScore W2946435265C50171091 @default.
• W2946435265 hasConceptScore W2946435265C502942594 @default.
• W2946435265 hasConceptScore W2946435265C526584372 @default.
• W2946435265 hasConceptScore W2946435265C55493867 @default.
• W2946435265 hasConceptScore W2946435265C71924100 @default.
• W2946435265 hasFunder F4320335787 @default.
• W2946435265 hasIssue "7" @default.

• next